Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares. The sale was executed at a weighted average price of $20.8095 per share, with individual trade prices ranging from $20.5400 to $21.3900.
After this transaction, Webster directly holds 395,467 common shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Kestra Medical Technologies, Ltd. reported Form 144 filings showing proposed and completed dispositions of 15,000 common shares under an issuer equity compensation plan. The filing lists a restricted share issuance dated 01/21/2026 and multiple sales by Brian Webster of 15,000 shares each on 02/17/2026, 03/17/2026, 04/15/2026 and 05/15/2026, with dollar amounts shown per trade.
Moran Timothy P. reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies reported that Chief Business Officer Timothy P. Moran received a grant of 22,704 restricted stock units (RSUs), each representing one common share at settlement. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to his continued service. Following this award, Moran holds 42,261 common shares directly. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Ford Alfred J Jr reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies Chief Commercial Officer receives equity award. Alfred J. Ford Jr. was granted 25,227 restricted stock units, each representing one common share at settlement and awarded at no cash cost. Subject to continued service, the RSUs will vest over three years, with one-third vesting on each anniversary of June 3, 2026. After this grant, his reported direct holdings total 74,639 common shares or share-equivalent units.
Mahboob Vaseem reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported an equity compensation grant in the form of restricted stock units. He was awarded 25,227 RSUs that each entitle him to receive one common share at settlement. Subject to his continued service, one third of these RSUs will vest on each anniversary of June 3, 2026, over a three-year period. Following this grant, he beneficially owns 67,961 common shares, which include 5,837 common shares received in a prior pro rata distribution from West Affum Holdings, L.P. that was exempt under Rule 16a-9.
Umberger Traci S reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director and officer Traci S. Umberger received a grant of 25,227 restricted stock units (RSUs). These RSUs entitle her to one common share per unit upon settlement and will vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to continued service. Following this equity award, her direct holdings increased to 161,860 common shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.
Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director and officer Brian Daniel Webster received an equity grant of 75,681 restricted stock units (RSUs), each settling into one common share at no purchase price. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, contingent on his continued service. Following this grant, Webster is reported as beneficially owning 410,467 common shares, showing his overall equity stake including this new award.
Kestra Medical Technologies director and officer Brian Daniel Webster reported selling a total of 15,000 Common Shares in open-market transactions. The sales occurred on May 15, 2026 at weighted average prices of $21.4635 and $20.5287 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Kestra Medical Technologies notice of proposed resale: a reporting holder filed a Rule 144 notice to sell 15,000 restricted common shares granted under the issuer's equity compensation plan on 01/21/2026. The filing lists three prior sales by the same holder: 15,000 shares on 02/17/2026 for $384,020.06, 15,000 shares on 03/17/2026 for $304,123.49, and 15,000 shares on 04/15/2026 for $300,671.04.
Kestra Medical Technologies director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares on April 15, 2026 at a weighted average price of $20.0447 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Webster now holds 349,786 common shares directly.